Resumen
Improving spinal fusion by optimizing scaffold and surface engineering is a topic of interest for both surgeons and researchers. Concerns regarding patient safety with off-label use of bone morphogenetic protein (BMP) have increased, and patients are choosing minimally invasive spine surgery to lessen morbidity by avoiding harvest of bone graft. These trends may be driving studies on how surgeons can avoid issues associated with biologics (e.g., cost, morbidity), while achieving efficacious and safe bone fusion.
Idioma original | English (US) |
---|---|
Páginas (desde-hasta) | S14-S15 |
Publicación | Spine |
Volumen | 41 |
DOI | |
Estado | Published - 2016 |
Publicado de forma externa | Sí |
ASJC Scopus subject areas
- Clinical Neurology
- Orthopedics and Sports Medicine